Navigation Links
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
Date:3/17/2008

-Webcast to Be Held at 4:30 p.m. ET today-

SAN CARLOS, Calif., March 17 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that data from the Phase 2 program in catheter occlusion (CO), known as SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase), did not show sufficient improvement in catheter opening at the higher dose and concentration evaluated in the study to meet the desired target product profile. As a result, Nuvelo has ended further clinical development of alfimeprase including its programs in CO and acute ischemic stroke.

In the open-label, single-arm, SONOMA-3 trial, alfimeprase restored catheter function in approximately 50 percent of patients at 15 minutes and approximately 60 percent of patients at one hour. While the 15-minute clearance rate represents an improvement over the previous Phase 3 SONOMA-2 trial, which evaluated a lower dose and concentration of alfimeprase than the SONOMA-3 trial, the clearance rate at one hour fell short of the company's expectations. Cathflo(R)Activase(R), the product currently on the market for catheter occlusion, has been shown to restore catheter function in more than 80 percent of occluded catheters within two to four hours.

"The value proposition for alfimeprase in CO was to restore catheter function with similar efficacy to CathfloActivase, but in a much shorter time frame. We did not see the robust increase in activity or dose response expected with the significantly increased dose and concentration we tested in the SONOMA-3 trial," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "We have conducted high-quality, comprehensive development of alfimeprase and are confident
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
3. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
4. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
5. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
6. Synbiotics Corporation Announces Human Submission for FluDetect(R)
7. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
8. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
9. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
10. Inclinix Announces New Patent for Expert System Platform
11. Genzyme Announces Presentation of New Positive Data on Carticel(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Diseases largely eradicated in ... are returning. Measles was declared eliminated in 2000, yet ... of August 15—the highest incidence in 20 years. In ... declared whooping cough a problem of "epidemic proportions." ... and dying from these preventable diseases—in part because some ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present ... Australian and New Zealand Forensic Science Society,s 22 ... in Adelaide, Australia .  Forensic ... the advancements that hyperspectral imaging can bring to ... Beckstead , Director of Product Development at ChemImage, ...
(Date:8/29/2014)... Aug. 29, 2014  In part four ... a hospital pharmacy as a strategic asset, Mary ... leader for Cardinal Health,s Innovation Delivery Solutions business, discusses ... benefit both hospitals and patients. "Every hospital ... part of their job in a value-based healthcare world," ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
(Date:9/1/2014)... 2014: Daily fruit consumption cuts the risk of cardiovascular ... presented at ESC Congress today by Dr Huaidong Du ... follow-up study of nearly 0.5 million people in the ... ate, the more their risk of CVD declined. , ... and stroke, is the leading cause of death worldwide. ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 As well ... training, Derek is currently pursuing counselor certification in Louisiana. ... advance through the CPI training program as well as ... I have grown both personally and professionally. I ... I am competently able to do so. As ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
(Date:9/1/2014)... 2014 In honor of National Take Your Cat ... Emergency & Referral Center of Minnesota (AERC) is offering a few ... their cats. , Many people don’t take their cat to the ... hassle,” but they wouldn’t decide not to take their kid to ... The same goes for pets. Just like people want their loved ...
(Date:9/1/2014)... Registration is now open for the 4th Annual Harmon Meadow ... held on Sunday, September 21, 2014. The event will be ... Secaucus, New Jersey. All proceeds from the race will benefit ... a sense of self, restoring the family unit, and restoring ... General registration is $30 with special pricing for veterans, military ...
Breaking Medicine News(10 mins):Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... abandoned again! WEST PALM BEACH, Fla., April 30 ... civil rights and negligence lawsuit in New York District ... Administration and four other agencies for failure to prevent ... foster parent.Identified in the filing only by their initials, ...
... in daily life: 56 percent of workers use one ... one. Arthritis is a leading cause of work disability, ... physically demanding jobs, and may select jobs that appear ... is a risk factor for pain and musculoskeletal disorders ...
... and others?,What can I do to prevent spreading swine flu? ... the threatening pandemic of "Swine,Flu", where time is of essence ... The Internet News Distribution Channel FEEDZILLA updates news ... "Help stop the,Flu" is available as a widget to be ...
... April 30 The following is being issued by Randall ... Noon, protests will occur on Notre Dame campus ... least one dozen pro-life activists will push baby carriages holding ... the lunch hour on May 1.In addition, life size images ...
... But few options require balancing dangers and benefits, experts ... The risk of developing leukemia from a drug used ... than previously reported, new research shows. , Italian researchers ... an estimated 7.4 people will develop acute leukemia, compared ...
... Shamir Optical Industry Ltd. (Nasdaq: SHMR ) ... technology to the ophthalmic lens market, today announced that it ... chief executive officer, replacing Mr. Eyal Hayardeny who has resigned ... become effective on July 1, 2009.Mr. Netzer currently serves as ...
Cached Medicine News:Health News:Severely Abused Foster Children Sue New York City Child Welfare Agencies After their Failure to Help Them 2Health News:Computer use significantly affected by arthritis 2Health News:Computer use significantly affected by arthritis 3Health News:Leukemia Risk From MS Drug May Be Up 2Health News:Leukemia Risk From MS Drug May Be Up 3Health News:Shamir Optical Industry Ltd. Appoints Amos Netzer as New Chief Executive Officer 2Health News:Shamir Optical Industry Ltd. Appoints Amos Netzer as New Chief Executive Officer 3
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. The classic Goldmann Glass....
This table provides the user with a moderatelypriced, yet fully versatile, electric table which will accept most HAAG-STREIT instruments as well as many of those from other ophthalmic manufacturers....
... The design philosophy of the Uniflex® ... system that could be used for the ... on a closed interlocking intramedullary rod, the ... understanding of the biology of fracture healing ...
... in the Magnes line of biomagnetometer systems, with ... cortical coverage, provides the highest detector density available, ... a wide range of neuronal activity. The Magnes ... configurations and can be equipped with radial magnetometers, ...
Medicine Products: